Holzer & Holzer, LLC announced an investigation into AdaptHealth Corp. following the company's revised financial guidance and second quarter 2026 results. AdaptHealth reported a decrease in cash flow from operations to $239 million year-to-date 2026, down from $257.5 million in the same period in 2025, and a negative free cash flow of $48.4 million compared to positive $73.3 million previously. The company cited the full-scale launch and complex transition of its West Coast capitated partnership as factors impacting margins. The stock price fell after this announcement, prompting legal action offers for affected investors.
AdaptHealth reported a challenging Q2 with a loss of $1.07 per share and a $106 million revenue shortfall, prompting a lowered profitability outlook. Despite these setbacks, its core Sleep Health and Respiratory Health segments grew strongly, with ne...
AdaptHealth sharply reduced its full-year 2026 adjusted EBITDA guidance from $680-$730 million to approximately $490-$520 million, causing its stock to fall by up to 26%. The company initially cited elevated labor costs normalizing, but later attribu...
AdaptHealth's shares dropped over 30% following a disappointing Q2 report, including a $1.07 loss per share and missing revenue by $106 million. The company is selling its low-margin diabetes business to Cardinal Health for $235 million to concentrat...
Stocks fell sharply due to various factors including a 58.71% drop in the Defiance Daily Target 2x Short PLTR ETF, driven by strong gains in Palantir Technologies, which the ETF inversely tracks. AdaptHealth shares dropped 38.09% amid a legal investi...
